- Page 5/6
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It should be considered higher risk income, but it has a long history. Management is decent. It has survived many downturns and has managed to grow. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It should be considered higher risk income, but it has a long history. Management is decent. It has survived many downturns and has managed to grow. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The sell off today is probably over done. If the deal doesn’t go through, which is highly probable, the stock should bounce back. If it goes through, management has executed well in the past so it should be okay. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The sell off today is probably over done. If the deal doesn’t go through, which is highly probable, the stock should bounce back. If it goes through, management has executed well in the past so it should be okay. Unlock Premium - Try 5i Free
